AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Longboard Pharmaceuticals Inc (NASDAQ:LBPH)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 59.98 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 28.150/3.600 |
| EBITDA (in USD) | -62.902M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -2.25 |
| Total Assets (in USD) | 50.697M |
|---|---|
| Total Liabilities (in USD) | 9.774M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 14.331M |
| Market Cap (in USD) | 730.946 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
4275 Executive Square, La Jolla, CA, United States, 92037
858-789-9283
Employees: 50
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Kevin R. Lind | Pres, CEO, Sec. & Director | 1976 |
| 2. | Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer | 1974 |
| 3. | Mr. Chadwick J. Orevillo MPH | VP & Head of Operations | NA |
| 4. | Megan E. Knight | Head of Investor Relations | NA |
| 5. | Mr. Steven W. Spector J.D. | Head of Bus. Devel. & Gen. Counsel | 1965 |
| 6. | Dr. Anne M. Danks | VP & Head of Preclinical Devel. | NA |
| 7. | Dr. Jodi Parsons | VP & Head of Regulatory Affairs | NA |
| 8. | Dr. Randall E. Kaye M.D. | Chief Medical Officer | 1962 |
| 9. | Gus Cardenas | VP & Head of Quality Assurance | NA |
| 10. | Dr. Marco Peters Ph.D. | VP & Head of Translational Science | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Income Before Tax | -43.945M | -27.797M | -14.4M |
| Minority Interest | - | - | - |
| Net Income | -43.092M | -27.733M | -14.4M |
| Selling General Administrative | 10.16M | 8.065M | 9.767M |
| Gross Profit | - | - | - |
| Reconciled Depreciation | 0.005M | 0.001M | - |
| Ebit | -44.803M | -27.839M | -14.4M |
| Ebitda | -44.798M | -27.838M | -14.4M |
| Depreciation And Amortization | 0.005M | 0.001M | - |
| Operating Income | -44.798M | -27.839M | -14.4M |
| Other Operating Expenses | 44.798M | 27.839M | 14.4M |
| Interest Expense | 0.837M | 0.042M | 0M |
| Tax Provision | - | - | - |
| Interest Income | 0.837M | 0.064M | - |
| Net Interest Income | 0.837M | 0.064M | - |
| Income Tax Expense | -0.853M | -0.064M | - |
| Total Revenue | 0M | 0M | 0M |
| Total Operating Expenses | 44.798M | 27.839M | 14.4M |
| Cost Of Revenue | - | - | - |
| Total Other Income Expense Net | 0.853M | 0.042M | - |
| Net Income From Continuing Ops | -44.489M | -27.797M | -14.4M |
| Net Income Applicable To Common Shares | -43.945M | -27.797M | -14.4M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|
| Total Assets | 50.697M | 70.616M | 108.952M | 56.238M |
| Intangible Assets | - | - | - | - |
| Other Current Assets | 1.723M | 2.249M | 1.659M | 0.046M |
| Total Liab | 9.774M | 9.146M | 5.629M | 3.135M |
| Total Stockholder Equity | 40.923M | 61.47M | 103.323M | 53.103M |
| Other Current Liab | 8.773M | 7.096M | 0.339M | 1.922M |
| Common Stock | 0.002M | 0.001M | 0.001M | - |
| Capital Stock | 0.002M | 0.001M | 0.001M | 55.795M |
| Retained Earnings | -140.564M | -86.142M | -42.197M | -14.4M |
| Good Will | - | - | - | - |
| Other Assets | 0M | 0.033M | 0.033M | 0.876M |
| Cash | 14.331M | 10.775M | 66.346M | 55.316M |
| Cash And Equivalents | - | - | - | - |
| Total Current Liabilities | 9.774M | 8.764M | 5.444M | 3.135M |
| Current Deferred Revenue | -0.475M | - | 3.738M | - |
| Net Debt | -13.856M | -10.035M | -65.822M | -55.316M |
| Short Term Debt | 0.475M | 0.358M | 0.339M | - |
| Short Long Term Debt | - | - | - | - |
| Short Long Term Debt Total | 0.475M | 0.74M | 0.524M | - |
| Other Stockholder Equity | 181.563M | 148.303M | 36.731M | 11.708M |
| Property Plant Equipment | - | 0.009M | 0.535M | - |
| Total Current Assets | 50.221M | 69.838M | 108.384M | 55.362M |
| Long Term Investments | - | 0.033M | - | - |
| Short Term Investments | 34.167M | 56.814M | 40.379M | - |
| Net Receivables | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | 1.001M | 1.31M | 1.028M | 1.213M |
| Accumulated Other Comprehensive Income | -0.078M | -0.692M | -0.164M | - |
| Non Currrent Assets Other | - | 0.033M | 0.033M | 0.876M |
| Non Current Assets Total | 0.476M | 0.778M | 0.568M | 0.876M |
| Capital Lease Obligations | 0.475M | 0.74M | 0.524M | - |
| Long Term Debt Total | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Investments | -17.064M | -40.7M | -40.7M |
| Total Cashflows From Investing Activities | -17.064M | -40.716M | -40.716M |
| Total Cash From Financing Activities | -0.444M | 76.451M | 58.758M |
| Net Income | -43.945M | -27.797M | -14.4M |
| Change In Cash | -55.571M | 11.03M | 55.316M |
| Begin Period Cash Flow | 66.346M | 55.316M | 0M |
| End Period Cash Flow | 10.775M | 66.346M | 55.316M |
| Total Cash From Operating Activities | -38.063M | -24.705M | -3.442M |
| Depreciation | 0.005M | 0.001M | 0.001M |
| Other Cashflows From Investing Activities | - | - | - |
| Dividends Paid | - | - | - |
| Change To Inventory | - | - | - |
| Sale Purchase Of Stock | 0M | -0.001M | - |
| Other Cashflows From Financing Activities | -0.444M | -8.322M | 58.758M |
| Capital Expenditures | 0M | 0.016M | 0.016M |
| Change In Working Capital | 3.119M | 0.967M | 2.45M |
| Other Non Cash Items | 0.101M | 0.157M | - |
| Free Cash Flow | -38.063M | -24.721M | -3.442M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Select Biotechnology | 2 years ago | 1778489 |
| 2. | Polar Capital Biotech S Inc | 2 years ago | 1250000 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1094394 |
| 4. | US Small-Cap Growth II Equity Comp | 2 years ago | 872701 |
| 5. | T. Rowe Price New Horizons | 2 years ago | 872701 |
| 6. | T. Rowe Price Health Sciences | 2 years ago | 838874 |
| 7. | iShares Russell 2000 ETF | 2 years ago | 573261 |
| 8. | Fidelity Global Innovators Cl F | 2 years ago | 539798 |
| 9. | Fidelity Series Small Cap Opps | 2 years ago | 503000 |
| 10. | Fidelity Advisor Biotechnology I | 2 years ago | 445970 |
| 11. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 386285 |
| 12. | Wellington Global Hlthcr Eq USD G Ac | 2 years ago | 361761 |
| 13. | PGIM Jennison Health Sciences Z | 2 years ago | 338184 |
| 14. | Jennison Health Sciences Equity | 2 years ago | 338184 |
| 15. | Fidelity Stock Selector Small Cap | 2 years ago | 266500 |
| 16. | American Century Small Cap Growth Inv | 2 years ago | 228273 |
| 17. | American Century U.S. Small Cap Growth | 2 years ago | 228273 |
| 18. | Fidelity VIP Mid Cap Initial | 2 years ago | 214700 |
| 19. | Renaissance Global Health Care | 2 years ago | 212178 |
| 20. | JPMorgan US Small Company L | 2 years ago | 192063 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Farallon Capital Management, L.L.C. | 2 years ago | 5790500 |
| 2. | Cormorant Asset Management, LLC | 2 years ago | 3353141 |
| 3. | T. Rowe Price Associates, Inc. | 2 years ago | 2217995 |
| 4. | Vanguard Group Inc | 2 years ago | 1724431 |
| 5. | FMR Inc | 2 years ago | 1649503 |
| 6. | Polar Capital Holdings PLC | 2 years ago | 1305431 |
| 7. | Viking Global Investors LP | 2 years ago | 981328 |
| 8. | Jennison Associates LLC | 2 years ago | 942404 |
| 9. | Integral Health Asset Management, LLC | 2 years ago | 900000 |
| 10. | BlackRock Inc | 2 years ago | 869879 |
| 11. | Parkman Healthcare Partners LLC | 2 years ago | 693144 |
| 12. | Pictet Asset Manangement SA | 2 years ago | 576676 |
| 13. | Marshall Wace Asset Management Ltd | 2 years ago | 566498 |
| 14. | JPMorgan Chase & Co | 2 years ago | 534716 |
| 15. | Millennium Management LLC | 2 years ago | 533035 |
| 16. | Lord, Abbett & Co LLC | 2 years ago | 475179 |
| 17. | Driehaus Capital Management LLC | 2 years ago | 388472 |
| 18. | CIBC Global Asset Management Inc | 2 years ago | 342126 |
| 19. | Geode Capital Management, LLC | 2 years ago | 334661 |
| 20. | State Street Corporation | 2 years ago | 298467 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...